CD274 and neoplasm: Inhibitors of programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) activate tumor-specific T cells and provide therapeutic efficacy.